6A3A Stock Overview A clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Autolus Therapeutics plc Competitors Price History & Performance
Summary of share price highs, lows and changes for Autolus Therapeutics Historical stock prices Current Share Price US$2.30 52 Week High US$7.10 52 Week Low US$2.12 Beta 2.05 1 Month Change -16.67% 3 Month Change -37.84% 1 Year Change -62.30% 3 Year Change -38.83% 5 Year Change -79.46% Change since IPO -88.59%
Recent News & Updates
Autolus Therapeutics plc Announces Publication of Data from the Felix Study of Obe-Cel in R/R Adult B-All Patients in the New England Journal of Medicine Dec 02
Autolus Therapeutics plc Announces FDA Approval of AUCATZYL for Adults with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (r/r B-ALL) Nov 09
Autolus Therapeutics plc to Report Q3, 2024 Results on Nov 12, 2024 Oct 29
Autolus Therapeutics plc Appoints Matthias Will as Chief Development Officer, Effective September 30, 2024 Sep 19
Autolus Therapeutics plc Presents Clinical Data Update at the Society of Hematologic Oncology Annual Meeting Aug 27
High number of new directors Aug 13 See more updates
Autolus Therapeutics plc Announces Publication of Data from the Felix Study of Obe-Cel in R/R Adult B-All Patients in the New England Journal of Medicine Dec 02
Autolus Therapeutics plc Announces FDA Approval of AUCATZYL for Adults with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (r/r B-ALL) Nov 09
Autolus Therapeutics plc to Report Q3, 2024 Results on Nov 12, 2024 Oct 29
Autolus Therapeutics plc Appoints Matthias Will as Chief Development Officer, Effective September 30, 2024 Sep 19
Autolus Therapeutics plc Presents Clinical Data Update at the Society of Hematologic Oncology Annual Meeting Aug 27
High number of new directors Aug 13
Autolus Therapeutics plc to Report Q2, 2024 Results on Aug 08, 2024 Jul 26
Autolus Therapeutics plc to Present Three Clinical Data Updates on Obecabtagene Autoleucel (obe-cel) in Relapsed/Refractory B-Cell Acute L-Cell Acute Lymphoblastic Leukemia (All) Patients at the 2024 European Hematology Association (EHA) Congress Jun 15
Autolus Therapeutics plc, Annual General Meeting, Jun 28, 2024 Jun 08
Autolus Therapeutics plc Presents Long-Term Follow-Up and Additional Data Analysis of Pivotal Phase 2 FELIX Study of Obecabtagene Autoleucel in an Oral Presentation at ASCO Jun 01 Autolus Therapeutics plc announced delayed 10-Q filing May 15
High number of new directors May 01
Autolus Therapeutics plc to Report Q1, 2024 Results on May 14, 2024 Apr 24 Autolus Therapeutics Announces Changes to its Board of Directors
New major risk - Shareholder dilution Mar 26
Full year 2023 earnings released: US$1.20 loss per share (vs US$1.57 loss in FY 2022) Mar 15 Autolus Therapeutics plc Receives Medicines and Healthcare Products Regulatory Agency (MHRA) Certification for Nucleus Commercial Manufacturing Site Mar 14
Autolus Therapeutics plc to Report Fiscal Year 2023 Results on Mar 14, 2024 Mar 01
Forecast to breakeven in 2026 Feb 12
New minor risk - Shareholder dilution Feb 09 Autolus Therapeutics plc has completed a Follow-on Equity Offering in the amount of $350.000016 million. Feb 09
Autolus Therapeutics plc announced that it expects to receive $220.000002 million in funding from BioNTech SE Feb 08
High number of new directors Feb 01
Autolus Therapeutics plc Announces Acceptance of Biologics License Application for Obecabtagene Autoleucel as Potential Treatment for Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia Jan 22
Autolus Therapeutics plc Announces the Appointment of Robert W. Azelby to Its Board of Directors Jan 10
Autolus Therapeutics plc Announces Changes to Its Board of Directors, Effective December 31, 2023 Dec 22
Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for Obecabtagene Autoleucel for Patients with Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia Nov 29
Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for Obecabtagene Autoleucel for Patients with Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia Nov 28
Autolus Therapeutics plc to Report Q3, 2023 Results on Nov 02, 2023 Oct 12
Autolus Therapeutics plc Announces Data from Auto1/22 Trial in Pediatric Acute Lymphoblastic Leukemia Published in the Journal Blood Sep 06 Autolus Therapeutics plc Announces CFO Changes
Autolus Therapeutics Announces Publication in Nature Medicine on Obe-Cel in Pediatric Acute Lymphoblastic Leukemia Jul 07
Autolus Therapeutics plc Appoints Robert Iannone as Non-Executive Director Jun 22
Autolus Therapeutics plc Presents Positive Results from AUTO4 in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma Jun 17
Autolus Therapeutics plc, Annual General Meeting, Jun 30, 2023 Jun 07
Autolus Therapeutics plc Presents Positive Results from Pivotal Phase 2 Felix Study in Adult R/R B-All At Asco Jun 03
First quarter 2023 earnings released: US$0.23 loss per share (vs US$0.41 loss in 1Q 2022) May 07
Full year 2022 earnings released: US$1.57 loss per share (vs US$1.97 loss in FY 2021) Mar 08
Autolus Therapeutics plc to Report Q4, 2022 Results on Mar 07, 2023 Feb 16
Autolus Therapeutics plc Announces Board Changes Jan 21
Autolus Therapeutics plc Announces Pivotal Phase 2 Felix Clinical Trial Has Met Primary Endpoint At Interim Analysis Dec 09
Third quarter 2022 earnings released: US$0.47 loss per share (vs US$0.47 loss in 3Q 2021) Nov 05
Autolus Therapeutics plc to Report Q3, 2022 Results on Nov 03, 2022 Oct 22
Second quarter 2022 earnings released: US$0.46 loss per share (vs US$0.47 loss in 2Q 2021) Aug 05
Autolus Therapeutics plc to Report Q2, 2022 Results on Aug 04, 2022 Jul 22
Autolus Therapeutics plc, Annual General Meeting, Jun 28, 2022 Jun 01
First quarter 2022 earnings released: US$0.41 loss per share (vs US$0.53 loss in 1Q 2021) May 06 Autolus Therapeutics plc to Report Q1, 2022 Results on May 05, 2022
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Mar 11
Autolus Therapeutics plc to Report Q4, 2021 Results on Mar 10, 2022 Feb 22
Autolus Therapeutics plc Presents Positive Obecabtagene Autoleucel Data at 63rd ASH Annual Meeting & Exposition Dec 14
Third quarter 2021 earnings released: US$0.47 loss per share (vs US$0.72 loss in 3Q 2020) Nov 04
Second quarter 2021 earnings released: US$0.47 loss per share (vs US$0.62 loss in 2Q 2020) Aug 06
Autolus Therapeutics Announces Innovation Licensing and Access Pathway Designation for Obe-Cel for the Treatment of Relapsed/Refractory Adult B-Cell ALL Jun 16
Autolus Therapeutics Announces an Additional Nature Publication for AUTO1 May 26
Autolus Therapeutics plc Announces to Present New Data on AUTO1 in r/r Indolent B Cell Lymphomas at the European Hematology Association Virtual Congress May 13
First quarter 2021 earnings released: US$0.53 loss per share (vs US$0.60 loss in 1Q 2020) May 06
Full year 2020 earnings released: US$2.76 loss per share (vs US$2.88 loss in FY 2019) Mar 07
Revenue beats expectations Mar 07
New 90-day low: €5.45 Feb 24
Autolus Therapeutics plc to Report Q4, 2020 Results on Mar 04, 2021 Feb 05
New 90-day low: €6.15 Jan 30
New 90-day low: €7.55 Dec 11
Autolus Therapeutics plc Presents Additional Data on AUTO3 in DLBCL During the 62Nd ASH Annual Meeting Dec 10
Autolus Therapeutics Presents Compelling AUTO1 Data from ALLCAR Phase 1 Study in Adult Acute Lymphoblastic Leukemia (ALL) During the 62nd ASH Annual Meeting Dec 06
Autolus Therapeutics plc Announces Publication of New AUTO6 Phase 1 Data in Childhood Neuroblastoma in Science Translational Medicine Dec 01
New 90-day low: €8.55 Nov 12
Third quarter 2020 earnings released: US$0.72 loss per share Nov 07
Revenue beats expectations Nov 07
Autolus Therapeutics plc to Report Q3, 2020 Results on Nov 05, 2020 Oct 31
New 90-day low: €9.50 Oct 01
Autolus Therapeutics plc Presents Additional Data on AUTO3 in DLBCL during the ESMO Virtual Congress 2020 Sep 18
New 90-day low - €9.95 Sep 08 Shareholder Returns 6A3A DE Biotechs DE Market 7D 2.7% 5.5% 1.2% 1Y -62.3% -3.7% 10.1%
See full shareholder returns
Return vs Market: 6A3A underperformed the German Market which returned 9.4% over the past year.
Price Volatility Is 6A3A's price volatile compared to industry and market? 6A3A volatility 6A3A Average Weekly Movement 11.5% Biotechs Industry Average Movement 7.4% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.5% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 6A3A's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 6A3A's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company’s clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma.
Show more Autolus Therapeutics plc Fundamentals Summary How do Autolus Therapeutics's earnings and revenue compare to its market cap? 6A3A fundamental statistics Market cap €622.56m Earnings (TTM ) -€262.31m Revenue (TTM ) €9.80m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 6A3A income statement (TTM ) Revenue US$10.09m Cost of Revenue US$128.22m Gross Profit -US$118.12m Other Expenses US$152.10m Earnings -US$270.23m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.02 Gross Margin -1,170.59% Net Profit Margin -2,677.90% Debt/Equity Ratio 52.2%
How did 6A3A perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/09 16:59 End of Day Share Price 2025/01/09 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Autolus Therapeutics plc is covered by 13 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Ingrid Gafanhão Bryan Garnier & Co Rajan Sharma Goldman Sachs Biren Amin Jefferies LLC
Show 10 more analysts 
